Navigation Links
Thoratec Reports Third Quarter Fiscal 2011 Results
Date:11/1/2011

ip position of the HeartMate II® LVAS (Left Ventricular Assist System)," said Gary F. Burbach, president and chief executive officer of Thoratec.

"We also experienced a strong quarter with respect to new center development, as we added eight HeartMate II centers globally, including six in the U.S. and two internationally. As of the end of the third quarter, we had 280 HeartMate II centers worldwide, including 141 in the U.S. and 139 internationally, versus a total of 254 at the end of fiscal 2010," he added.

"Our continued growth is being facilitated by our market development and clinical education programs. In addition, the ongoing flow of data is demonstrating compelling long-term outcomes in HeartMate II patients, including  data published recently in leading peer-reviewed journals," he said.

One of the recent data publications, which appeared in the October edition of The Annals of Thoracic Surgery, compared outcomes from nearly 1,500 commercial bridge-to-transplantation (BTT) HeartMate II patients with those of nearly 500 patients who participated in the HeartMate II BTT clinical trial. The findings included Kaplan-Meier survival of 89 percent at six months and 85 percent at one year for commercial patients. In addition, commercial patients experienced declines in most adverse events versus patients in the trial, with catastrophic events such as device replacement and stroke occurring in just one percent and six percent of patients, respectively. "This dataset demonstrates excellent and improving outcomes for HeartMate II patients in a real-world setting among a broad range of implanting centers," Burbach noted.

Burbach also commented on the company's acute surgical support franchise, including the acquisition of the Levitronix Medical business during the third quarter. The acquired business remains on track to add approximately $4.0 million of incremental product sales in 2011, including CentriMag® outside the U.S. an
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
5. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
6. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
7. Thoratec Presentation at Canaccord Adams Conference to be Webcast
8. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
9. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
10. Thoratec Presentation at Piper Jaffray Conference to be Webcast
11. Thoratec Presentation at Raymond James Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Massachusetts General Hospital (MGH), the ... ) announced today that they have launched a ... therapeutic targets and develop novel therapies for inflammatory ... millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... following is being released by SafeMinds ( www.SafeMinds.org ): ... has publicly denied a vaccine-autism link, while at the ... been awarding damages for vaccine injury to children with ... on verifiable government data, breaks ground in the controversial ...
... Perrigo Company (Nasdaq: PRGO ; TASE) today ... relating to fluticasone lotion brought by Nycomed US Inc. by ... of the settlement, Perrigo can launch a generic version of ... certain circumstances. Cutivate® (fluticasone) lotion is indicated ...
Cached Medicine Technology:83 Cases of Autism Associated with Childhood Vaccine Injury Compensated in Federal Vaccine Court 2Perrigo Announces Settlement of Cutivate Lotion Litigation 2
(Date:4/18/2014)... 18, 2014) Benaroya Research Institute at Virginia Mason ... a particular molecule in metastatic breast cancer reduces both ... lung metastases. BRI scientists have found in models of ... by 60 - 80 percent and can keep the ... $1.8 million five-year grant comes from the National Cancer ...
(Date:4/18/2014)... 18, 2014) ― A new study in the ... in health-related Google searches reveals a recurring pattern that ... , Investigators from San Diego State University, the ... Campaigns, analyzed "healthy" Google searches (searches that included the ... originating in the U.S. from 2005 to 2012. They ...
(Date:4/18/2014)... Medicine scientists could lead to potential new treatments for ... scleroderma. , Fibrosis, or scarring, is a hallmark ... and lungs can lead to serious organ damage and, ... therapeutic options centers on findings made by Swati Bhattacharyya, ... role that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2
... , DALLAS, Jan. 11 The American ... effort led by the Department of Health and Human Services ... encourage more Americans to get vaccinated against H1N1. ... people with heart failure or with any cardiovascular disease. Like ...
... researchers suggest , MONDAY, Jan. 11 (HealthDay News) -- A ... genetic variant associated with the aggressiveness of prostate cancer, in ... out cancers that need intensive treatment from those that can ... principle to show that there are variants in the genome ...
... ... , ... Primary care physicians may be able to help increase Americans, willingness to become organ donors ... about end-of-life care, according to a study in the January issue of the Journal of ...
... , , BATESVILLE, Ind., Jan. 11 Hillenbrand, Inc. (NYSE: ... to 1:30 p.m. in New York, N.Y., on Jan. 14, 2010, and ... for Hillenbrand to acquire K-Tron International, Inc. ( KTII). , You are ... hear from and meet members of the Hillenbrand and K-Tron management teams ...
... , FAIRVIEW, Pa., Jan. 11 ... and manufacturer of custom electronic products and systems, today reported results ... , For the fourth quarter of fiscal 2009, the Company ... on sales of $34.1 million, compared to net income of $2.5 ...
... Amounts deemed safe are still too high, researchers say , ... of lead may harm children,s kidneys, say U.S. researchers. , ... per deciliter of blood, according to the U.S. Centers for ... Center study suggests that even levels below 10 micrograms are ...
Cached Medicine News:Health News:American Heart Association Encourages Heart Disease Patients to Get H1N1 Flu Shot in Support of National Influenza Vaccination Week, Jan. 10-16 2Health News:Genetic Marker for Aggressive Prostate Cancer Found 2Health News:Genetic Marker for Aggressive Prostate Cancer Found 3Health News:New Study Says Doctors' Offices -- Not the DMV -- Should Be Where Americans Decide to Become Organ Donors 2Health News:New Study Says Doctors' Offices -- Not the DMV -- Should Be Where Americans Decide to Become Organ Donors 3Health News:New Study Says Doctors' Offices -- Not the DMV -- Should Be Where Americans Decide to Become Organ Donors 4Health News:Hillenbrand to Host Investor Luncheons in New York City and Boston 2Health News:Hillenbrand to Host Investor Luncheons in New York City and Boston 3Health News:Hillenbrand to Host Investor Luncheons in New York City and Boston 4Health News:Hillenbrand to Host Investor Luncheons in New York City and Boston 5Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 2Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 3Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 4Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 5Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 6Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 7Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 8Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 9Health News:Very Low Levels of Lead Harm Kids' Kidneys: Study 2
ReNu 1 Step Enzymatic Cleaner with ReNu Multi-Purpose Solution removes protein deposits while lenses are being disinfected. Its a one-step process that saves time. Removes stubborn deposits from dai...
...
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
... intraocular lenses. The instrument consists of a ... implant and divides the implant into two ... halves of the lens so that unwanted ... chamber is avoided. The instrument is passed ...
Medicine Products: